Prevalence of Cerebral Small Vessel Disease in HIV Infected Patients

Prevalence of Cerebral Small Vessels Disease (CSVD) Among Patients Infected With HIV-1

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02082574

Acronym

MICROBREAK1

Enrollment

655

Registered

2014-03-10

Start date

2013-07-31

Completion date

Unknown

Last updated

2016-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Seropositivity

Brief summary

Cerebral small vessel disease (CSVD) is a major cause of cognitive impairment and disability in the general population, secondary to the accumulation of asymptomatic elementary lesions. CSVD is directly correlated with age and cardiovascular risk factors and therefore would be challenging in term of public health care in the future. While HIV patients share the same cardiovascular risk factors and they are often diagnosed with cognitive impairment and frailty, CSVD has not been yet described in this population. The global aim is to compare the prevalence of CSVD in a well controlled HIV+ population compared to HIV- controls matched with age and sex. 500 HIV+ patients and 250 age- and sex- matched controls will undergo a screening of the CSVD with a 10 minutes MRI (FLAIR and T2\*). Prevalence of the CSVD will be compared between HIV+ patients and controls. General and HIV-specific parameters from their electronic medical records will be compared between HIV+/CSVD+ and HIV+/CSVD- patients. We are expecting to prove that CSVD is more frequent in HIV+ population.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* age over 50 * chronic HIV seropositive patient infected for at least 5 years * treated with any antiretroviral (ARV) therapy * plasmatic HIV viral load \<40 copies/ml for at least one year with one authorized blip \< 1000 copies/ml per year

Exclusion criteria

* co-infection with hepatitis C virus (HCV) * uncontrolled high blood pressure (WHO criteria) * Personal history of cerebral infarction or cerebral ischemia * Personal history of neurological complication of the HIV-infection * Use of illegal drugs (except cannabis or poppers) * Glomerular filtration rate \< 15 mL/mn * Complicated diabetes mellitus (glomerular filtration rate \< 60ml/mn and/or proteinuria\> 300 mg and/or retinopathy)

Design outcomes

Primary

Measure	Time frame	Description
Cerebral small vessel disease	baseline	Cerebral small vessel disease detected with MRI

Countries

France

Outcome results